Last updated: October 29, 2026
ZALTRAP, the biologic oncology drug ziv-aflibercept, has become a mature and commercially limited product. Sanofi launched it in 2012 for metastatic colorectal cancer after oxaliplatin-based therapy, in combination with FOLFIRI. Its initial price, which exceeded $11,000 per treatment cycle, triggered hospital and physician resistance. Sanofi later cut the effective price by roughly 50% in the United States.
ZALTRAP’s commercial position weakened as colorectal cancer treatment became more competitive, treatment sequencing diversified, and payers favored lower-cost anti-VEGF alternatives. Sanofi no longer reports ZALTRAP as a major standalone growth product. The drug remains FDA-approved, but its revenue contribution is immaterial relative to Sanofi’s leading immunology, vaccines, rare-disease and specialty-care franchises.
What is ZALTRAP and how does it work?
ZALTRAP is ziv-aflibercept, a recombinant fusion protein that binds vascular endothelial growth factor A, VEGF-B and placental growth factor. It inhibits angiogenesis and is administered intravenously with FOLFIRI, a chemotherapy regimen containing irinotecan, fluorouracil and leucovorin.
The FDA approved ZALTRAP on August 3, 2012, for adults with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen. The approval was based primarily on the VELOUR trial, which compared FOLFIRI plus ziv-aflibercept with FOLFIRI plus placebo. [1]
| Metric |
ZALTRAP plus FOLFIRI |
FOLFIRI plus placebo |
| Median overall survival |
13.5 months |
12.06 months |
| Median progression-free survival |
6.9 months |
4.67 months |
| Objective response rate |
19.8% |
11.1% |
| Treatment setting |
Second-line metastatic colorectal cancer |
Second-line metastatic colorectal cancer |
ZALTRAP is a biologic product, but it is not interchangeable with EYLEA. Both contain aflibercept-related molecules, but ZALTRAP is ziv-aflibercept, an oncology formulation and dose, while EYLEA is aflibercept for ophthalmic injection. Their indications, dosage forms, manufacturing specifications and regulatory pathways differ.
What was ZALTRAP’s initial market strategy?
Sanofi and Regeneron positioned ZALTRAP as an anti-angiogenic option for patients whose metastatic colorectal cancer progressed after oxaliplatin. The product entered a market already containing Avastin, or bevacizumab, which was widely used with chemotherapy in colorectal cancer.
The launch price was the central commercial problem. The list price reported at launch was approximately $11,063 for a typical 28-day cycle, compared with about $2,200 for a comparable Avastin regimen at the time. The difference became a high-profile example of oncology pricing pressure and generated public criticism from Memorial Sloan Kettering Cancer Center and other treatment centers. [2]
Sanofi responded with a patient assistance and discount program that reduced the effective price by about 50% for eligible institutions. The price reduction protected access but reduced the product’s revenue ceiling and weakened the value proposition for future premium pricing.
Why did ZALTRAP struggle commercially?
The product faced four structural constraints:
- Its indication was restricted to a later-line metastatic colorectal cancer population.
- Its clinical benefit was incremental rather than practice-defining.
- Avastin offered a familiar anti-VEGF mechanism at a lower cost.
- Physicians and payers had other later-line options, including targeted therapy and oral agents.
The product also carried clinically important risks, including hypertension, hemorrhage, gastrointestinal perforation, impaired wound healing, proteinuria, neutropenia and arterial or venous thromboembolic events. These risks are common considerations for anti-VEGF treatment and increased the need for patient selection and monitoring. [1]
What are ZALTRAP’s main competitors?
ZALTRAP competes in a treatment environment rather than against a single direct substitute. The most relevant alternatives are shown below.
| Product |
Active ingredient |
Company |
Role in colorectal cancer |
Commercial implication |
| Avastin |
Bevacizumab |
Roche/Genentech |
Anti-VEGF therapy used across multiple colorectal cancer lines |
Broad physician familiarity and lower-cost competition |
| Cyramza |
Ramucirumab |
Eli Lilly |
Combination with FOLFIRI after progression on bevacizumab, oxaliplatin and a fluoropyrimidine |
Later-line anti-angiogenic alternative |
| Stivarga |
Regorafenib |
Bayer |
Oral multikinase inhibitor in refractory disease |
Avoids intravenous infusion but has substantial toxicity |
| Lonsurf |
Trifluridine/tipiracil |
Taiho/Servier |
Oral later-line therapy |
Competes for the same heavily pretreated population |
| Braftovi plus Erbitux |
Encorafenib plus cetuximab |
Pfizer/Merck KGaA |
Molecularly selected BRAF V600E colorectal cancer |
Removes some patients from the anti-VEGF addressable population |
| Keytruda and other checkpoint inhibitors |
Pembrolizumab and others |
Merck and competitors |
Microsatellite instability-high or mismatch-repair-deficient disease |
Biomarker-driven substitution in a defined subgroup |
Avastin is the most important commercial comparator because it is used with colorectal cancer chemotherapy and has a larger evidence base, wider oncology presence and stronger prescribing familiarity. Cyramza is the closest labeled competitor in the later-line FOLFIRI setting, although its approved sequence is narrower and its commercial scale is also modest relative to major oncology products. [3,4]
What is ZALTRAP’s financial trajectory?
ZALTRAP’s revenue peaked shortly after launch and then declined as pricing pressure, competition and treatment alternatives increased. Sanofi’s public financial reporting has not consistently disclosed ZALTRAP as a major standalone revenue line in recent years. The absence of a separately reported figure indicates that the product is no longer material to consolidated financial performance, not that the product has necessarily been formally withdrawn worldwide.
Sanofi’s reporting practice creates an important analytical limitation: historical product sales may appear in oncology or other-product categories, while later years may omit ZALTRAP from named-product tables. The financial trajectory is therefore best assessed directionally.
| Period |
Commercial position |
Financial interpretation |
| 2012 |
U.S. FDA approval and launch |
High initial price, rapid payer and provider resistance |
| 2013-2014 |
Discount program and broader market scrutiny |
Revenue growth constrained by net-price reduction |
| 2015-2018 |
Mature product with strong competitive pressure |
Declining or low-growth sales profile |
| 2019-2021 |
Reduced strategic visibility |
Product contribution increasingly immaterial to Sanofi |
| 2022 onward |
Mature, niche oncology product |
No disclosed evidence of meaningful growth or strategic expansion |
Sanofi’s principal financial exposure is limited. ZALTRAP is not comparable to Dupixent, vaccine products, rare-disease medicines or major specialty-care assets in revenue importance. A generic or biosimilar entrant would likely have limited impact on Sanofi’s group earnings, although it could accelerate erosion in the product’s remaining oncology revenue.
When does ZALTRAP lose exclusivity?
ZALTRAP does not have one single exclusivity date. Regulatory exclusivity and patent protection must be analyzed separately.
The product was approved as a biologic under a Biologics License Application, BLA 125418. FDA approval created a period of reference-product exclusivity under the Biologics Price Competition and Innovation Act. For a new biologic, the statutory reference-product exclusivity period is 12 years from first licensure, subject to the applicable FDA rules. That period would have expired in 2024 for a 2012 approval. [5]
| Protection type |
ZALTRAP position |
| FDA approval |
August 3, 2012 |
| BLA |
125418 |
| Reference-product exclusivity |
Statutory period reached its endpoint in 2024 |
| Patent protection |
Depends on patent family, claims, terminal disclaimers and applicable adjustments |
| Biosimilar pathway |
Potentially available under section 351(k) |
| Small-molecule generic pathway |
Not applicable |
The expiry of statutory biologic exclusivity does not automatically permit immediate market entry. A biosimilar applicant must obtain FDA approval, complete the relevant data package and address any enforceable patents. Patent protection can continue after regulatory exclusivity expires.
What patents protect ZALTRAP?
ZALTRAP is protected by patent families covering aflibercept-related fusion proteins, VEGF-binding constructs, formulations and manufacturing technology. The commercially relevant assessment is claim scope, not simply the existence of a patent mentioning aflibercept.
A patent review should separate:
- Composition claims covering the fusion protein or VEGF-binding molecule.
- Sequence and structural claims covering the receptor-immunoglobulin construct.
- Formulation claims covering liquid or frozen protein compositions.
- Manufacturing claims covering cell culture, purification and viral-clearance processes.
- Method-of-use claims covering administration with FOLFIRI for metastatic colorectal cancer.
- Patent-term adjustments, terminal disclaimers and continuations.
Several aflibercept patent families have expiration dates extending into the 2020s, but the enforceability of any particular patent depends on claim language, prosecution history, maintenance status and jurisdiction. ZALTRAP protection cannot be determined reliably from the EYLEA patent estate because EYLEA and ZALTRAP have different approved products and regulatory uses.
Are ZALTRAP patents listed in the Orange Book?
No. The FDA Orange Book primarily covers approved small-molecule drugs and associated patent and exclusivity information. Biologic patent information is not managed through the Orange Book in the same way.
For ZALTRAP, the relevant sources are:
- FDA’s BLA and product labeling records.
- FDA Purple Book information.
- USPTO patent records.
- Patent assignment and maintenance records.
- Court dockets for any BPCIA litigation.
- Sanofi and Regeneron intellectual-property disclosures.
The absence of an Orange Book entry does not mean that ZALTRAP has no patent protection.
Are there Paragraph IV challenges to ZALTRAP?
A Paragraph IV challenge is generally associated with an abbreviated new drug application for a small-molecule drug under the Hatch-Waxman Act. ZALTRAP is a biologic, so a conventional Paragraph IV generic challenge is not the expected pathway.
A competitor would more likely file a 351(k) biosimilar application and engage in the BPCIA patent-exchange process. Potential litigation could address patents covering:
- The ziv-aflibercept molecule.
- Protein sequence and receptor domains.
- Formulation and stability.
- Cell-line and manufacturing methods.
- The labeled colorectal cancer use.
Public evidence of a major, established BPCIA litigation campaign directed specifically at ZALTRAP is limited. That reduces the immediate litigation signal but does not remove biosimilar risk.
How strong is the ZALTRAP patent estate?
The patent estate is likely moderate rather than highly defensive.
Composition patents are the strongest potential barrier because they can prevent production of the reference molecule or a highly similar molecule until expiration. Formulation and manufacturing patents are narrower and may be designed around. Method-of-use patents may have limited practical value if a biosimilar applicant pursues a different label, uses indication carve-outs or relies on noninfringing treatment instructions.
The commercial strength of the estate is also constrained by the product’s limited market. A biosimilar developer is less likely to incur substantial litigation expense for a product with modest sales unless the same manufacturing platform supports higher-value aflibercept products or broader oncology commercialization.
Is ZALTRAP exposed to biosimilar competition?
Yes, but biosimilar entry risk is economically more important than strategically important for Sanofi.
Ziv-aflibercept is a complex recombinant protein. A biosimilar developer would need to demonstrate high similarity, address analytical comparability, establish an adequate manufacturing process and manage clinical and regulatory requirements. The process is more complex than filing a conventional generic drug application.
Potential barriers include:
- High development costs for a relatively small market.
- Complex protein analytics.
- Comparability of glycosylation and other critical quality attributes.
- Manufacturing scale and supply reliability.
- Physician acceptance in oncology.
- Payer contracting and rebate pressure.
- Patent litigation risk.
The commercial incentive improves if a competitor can leverage the same production platform for additional anti-VEGF or oncology products. Without that platform advantage, the addressable market may be too small to support multiple entrants.
What generic launch scenarios exist for ZALTRAP?
Three launch scenarios are commercially plausible.
Single biosimilar entrant
A first biosimilar could obtain preferred formulary placement by offering a discount against the post-discount net price rather than the original list price. In a small oncology market, first-mover status could produce meaningful share but limited absolute revenue.
Multiple biosimilar entrants
Several approved products would create rapid price erosion. Hospital systems and group purchasing organizations would likely use competitive bidding, particularly where physicians view the products as clinically interchangeable or easily substitutable.
No near-term biosimilar launch
The market may remain protected in practice if patent disputes, manufacturing complexity and low expected sales deter development. A product can lose formal exclusivity without attracting a commercial entrant.
The most probable outcome is gradual erosion rather than a large patent-cliff event. ZALTRAP’s declining base and limited strategic importance reduce the likelihood of a high-profile launch battle comparable to major ophthalmic or immunology biologics.
What is the FDA and regulatory status of ZALTRAP?
ZALTRAP remains an FDA-approved biologic for its labeled metastatic colorectal cancer indication. The product is administered intravenously with FOLFIRI and is not interchangeable with EYLEA.
Its regulatory profile has several commercial consequences:
- The labeled population is narrow.
- The product is used in combination, not as a standalone therapy.
- Treatment occurs in oncology infusion centers.
- Safety monitoring raises administration complexity.
- Biomarker-driven and oral treatments reduce the eligible population over time.
- The product does not have the broad multi-indication profile of leading biologics.
There is no basis to treat ZALTRAP as a developing growth asset unless Sanofi or a partner pursues new indications, combinations or dosing strategies. Public commercial signals do not indicate such an expansion strategy.
What licensing deals affect ZALTRAP?
ZALTRAP originated from the Sanofi-Regeneron collaboration involving vascular endothelial growth factor pathway assets. The collaboration is commercially important because it links ZALTRAP’s development history to Regeneron’s aflibercept platform, while Sanofi handled major commercial responsibilities for the oncology product.
The collaboration does not make ZALTRAP economically equivalent to EYLEA. EYLEA became the major commercial product from the aflibercept platform, while ZALTRAP remained a narrower oncology application. Regeneron’s financial disclosures have historically focused on the larger ophthalmology and immunology businesses rather than treating ZALTRAP as a material standalone driver. [6]
What is the outlook for ZALTRAP revenue?
ZALTRAP revenue is likely to remain flat at a low level or continue declining. The product lacks the characteristics associated with a durable growth trajectory:
- No broad expansion into new indications.
- No meaningful pricing power after the launch controversy.
- Strong anti-VEGF competition.
- A restricted treatment line.
- Increasing use of molecularly selected therapies.
- Limited reported strategic emphasis from Sanofi.
- Potential future biosimilar entry.
The most important value question is not whether ZALTRAP can regain growth. It is whether the remaining revenue stream is sufficient to justify continued commercial support, manufacturing capacity and patent enforcement.
How does ZALTRAP compare with EYLEA?
| Attribute |
ZALTRAP |
EYLEA |
| Active product |
Ziv-aflibercept |
Aflibercept |
| Therapeutic area |
Oncology |
Ophthalmology |
| Route |
Intravenous infusion |
Intravitreal injection |
| Main company association |
Sanofi and Regeneron |
Regeneron and Bayer outside the U.S. |
| Commercial scale |
Niche oncology product |
Major ophthalmology franchise |
| Primary competition |
Bevacizumab, ramucirumab, oral agents |
Lucentis, Beovu, Vabysmo and biosimilar aflibercept products |
| Regulatory analysis |
BLA and BPCIA framework |
Separate biologic product and patent estate |
| Revenue risk |
Mature-product decline |
High-value franchise erosion from competing biologics and biosimilars |
Investors should not use EYLEA’s patent litigation or revenue trajectory as a direct proxy for ZALTRAP. The products share scientific lineage but have different markets, labels, pricing structures and competitive dynamics.
Key Takeaways
- ZALTRAP is ziv-aflibercept, an intravenous biologic approved in 2012 for metastatic colorectal cancer with FOLFIRI.
- Its commercial launch was damaged by an unusually high price relative to Avastin.
- Sanofi’s subsequent discount program reduced the effective price and limited the product’s revenue potential.
- ZALTRAP now occupies a mature, narrow oncology niche with declining strategic importance.
- Its 12-year biologic reference-product exclusivity period reached its endpoint in 2024.
- Paragraph IV litigation is not the primary challenge mechanism because ZALTRAP is a biologic.
- A 351(k) biosimilar application is the more relevant future entry pathway.
- Patent protection may extend beyond regulatory exclusivity, but formulation, manufacturing and method-of-use claims are more vulnerable to design-around strategies than core composition claims.
- No major public biosimilar litigation campaign has established a near-term ZALTRAP launch threat.
- Sanofi’s financial exposure is limited because ZALTRAP is no longer a material standalone revenue driver.
- The most likely market outcome is gradual erosion, with the possibility of accelerated decline if a biosimilar gains approval and preferred payer placement.
FAQs About ZALTRAP Market and Patent Risk
Is ZALTRAP the same drug as EYLEA?
No. Both products are associated with aflibercept technology, but ZALTRAP is ziv-aflibercept for intravenous oncology use, while EYLEA is aflibercept for intravitreal ophthalmic use.
Can a generic drug replace ZALTRAP?
A conventional small-molecule generic is not the expected pathway. A competitor would generally pursue a biosimilar application under section 351(k) of the Public Health Service Act.
Why did Sanofi reduce ZALTRAP’s price?
Sanofi reduced the effective price after hospitals and physicians objected that the product cost substantially more than Avastin for an incremental survival benefit in colorectal cancer.
Does ZALTRAP have Orange Book patents?
No. Biologic products such as ZALTRAP are not handled through the Orange Book patent-listing framework used for conventional small-molecule drugs.
Could ZALTRAP sales materially affect Sanofi?
Unlikely. ZALTRAP is a small, mature product relative to Sanofi’s major businesses. Even substantial percentage erosion would have limited effect on consolidated company revenue.
References
- U.S. Food and Drug Administration. (2012). ZALTRAP (ziv-aflibercept) prescribing information.
- Pollack, A. (2012, August 7). Cancer drug offers survival gain at high cost. The New York Times.
- U.S. Food and Drug Administration. (2023). AVASTIN (bevacizumab) prescribing information.
- U.S. Food and Drug Administration. (2024). CYRAMZA (ramucirumab) prescribing information.
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, §7002.
- Regeneron Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.
- Sanofi. (2024). Universal registration document and annual financial report 2023.
